<info type="DiseaseOrPhenotypicFeature">Depression</info>, <info type="DiseaseOrPhenotypicFeature">impulsiveness</info>, <info type="DiseaseOrPhenotypicFeature">sleep</info>, and <info type="DiseaseOrPhenotypicFeature">memory</info> in past and present polydrug users of <info type="ChemicalEntity">3,4-methylenedioxymethamphetamine</info> (<info type="ChemicalEntity">MDMA</info>, <info type="ChemicalEntity">ecstasy</info>).

RATIONALE: <info type="ChemicalEntity">Ecstasy</info> (<info type="ChemicalEntity">3,4-methylenedioxymethamphetamine</info>, <info type="ChemicalEntity">MDMA</info>) is a worldwide recreational drug of abuse. Unfortunately, the results from human research investigating its psychological effects have been inconsistent. OBJECTIVES: The present study aimed to be the largest to date in sample size and <info type="GeneOrGeneProduct">5HT</info>-related behaviors; the first to compare present <info type="ChemicalEntity">ecstasy</info> users with past users after an abstinence of <info type="SequenceVariant">4</info> or more years, and the first to include robust controls for other recreational substances. METHODS: A sample of <info type="SequenceVariant">997</info> participants (<info type="SequenceVariant">52</info> % male) was recruited to four control groups (<info type="CellLine">non-drug</info> (<info type="CellLine">ND</info>), <info type="CellLine">alcohol/nicotine</info> (<info type="CellLine">AN</info>), <info type="CellLine">cannabis/alcohol/nicotine</info> (<info type="CellLine">CAN</info>), <info type="CellLine">non-ecstasy polydrug</info> (<info type="CellLine">PD</info>)), and two <info type="CellLine">ecstasy polydrug</info> groups (present (<info type="CellLine">MDMA</info>) and past users (<info type="CellLine">EX-MDMA</info>)). Participants completed a drug history questionnaire, <info type="GeneOrGeneProduct">Beck Depression Inventory</info>, <info type="GeneOrGeneProduct">Barratt Impulsiveness Scale</info>, <info type="GeneOrGeneProduct">Pittsburgh Sleep Quality Index</info>, and <info type="GeneOrGeneProduct">Wechsler Memory Scale-Revised</info> which, in total, provided <info type="SequenceVariant">13</info> psychometric measures. RESULTS: While the <info type="CellLine">CAN</info> and <info type="CellLine">PD</info> groups tended to record greater deficits than the <info type="CellLine">non-drug</info> controls, the <info type="CellLine">MDMA</info> and <info type="CellLine">EX-MDMA</info> groups recorded greater deficits than all the control groups on <info type="SequenceVariant">ten</info> of the <info type="SequenceVariant">13</info> psychometric measures. Strikingly, despite prolonged abstinence (<info type="SequenceVariant">mean</info>, <info type="SequenceVariant">4.98</info>; <info type="SequenceVariant">range</info>, <info type="SequenceVariant">4-9</info> years), past <info type="ChemicalEntity">ecstasy</info> users showed few signs of recovery. Compared with present <info type="ChemicalEntity">ecstasy</info> users, the past users showed no change for <info type="SequenceVariant">ten</info> measures, increased impairment for <info type="SequenceVariant">two</info> measures, and improvement on just <info type="SequenceVariant">one</info> measure. CONCLUSIONS: Given this record of impaired <info type="DiseaseOrPhenotypicFeature">memory</info> and clinically significant levels of <info type="DiseaseOrPhenotypicFeature">depression</info>, <info type="DiseaseOrPhenotypicFeature">impulsiveness</info>, and <info type="DiseaseOrPhenotypicFeature">sleep disturbance</info>, the prognosis for the current generation of <info type="ChemicalEntity">ecstasy</info> users is a major cause for concern.